Coronary stent ITRIX"
PLGAbioresorbabledrug eluting

coronary stent
coronary stent
Add to favorites
Compare this product
 

Characteristics

Type
coronary arteries
Material
PLGA
Options
bioresorbable, drug eluting
Diameter

2 mm, 2.5 mm, 3 mm, 3.5 mm, 4 mm
(0.079 in, 0.098 in, 0.118 in, 0.138 in, 0.157 in)

Length

10 mm, 14 mm, 18 mm, 24 mm, 38 mm
(0.394 in, 0.551 in, 0.709 in, 0.945 in, 1.496 in)

Description

The ITRIXII Rapamycin Eluting Coronary Stent Implantation System is the first carbonized stent (Inert Carbon Technology) with a completely biodegradable polymer coating which contains Rapamycin (Rapasorb™) as a highly effective drug for preventing thrombotic and re-stenotic events. Benefits > No stent thrombosis during the entire 2-year follow-up period > Polymer: Poly (D, L-Lactide-co-Glycolid) Polylactide 50% Polyglycolid 50% > Drug: Rapamycin > Coating Degradation: 6 weeks in-vivo > Drug load: 2.0μg/mm2 > 250 Patients with over two years follow-up The Coating The biodegradable Polymer contains Poly-lactic-co-glycolic acid (PLGA) which will degrade 100% into carbon dioxide and water. Rapamycin Eluting Coronary Stent Implantation System does not need any other auxiliary polymer like parylene C. The controlled polymer degradation and release of Rapamycin is designed to terminate simultaneously and is completed within less than three months. This covers exactly the time where the drug is needed at most and is tailored uniquely to various immune response reactions occurring after stent implantation. This is understood as Rapasorb™ - Technology.

Catalogs

ITRIXII
ITRIXII
2 Pages
*Prices are pre-tax. They exclude delivery charges and customs duties and do not include additional charges for installation or activation options. Prices are indicative only and may vary by country, with changes to the cost of raw materials and exchange rates.